Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Desert Lake Technologies is a specialized biotechnology company focused on the harvesting and processing of Aphanizomenon flos-aquae (AFA), a nutrient-dense blue-green microalga endemic to Upper Klamath Lake, Oregon. The company utilizes proprietary, gentle drying technologies to preserve the bioactive integrity of the algae, producing high-quality extracts for the dietary supplement, functional food, and cosmetic industries. Their research focuses on the health benefits of AFA components, such as phycocyanin and phenylethylamine, particularly regarding immune support, cognitive health, and stem cell mobilization. In 2021, Desert Lake Technologies was acquired by TCI Co., Ltd., a global leader in the nutraceutical and skincare ODM sector. This acquisition integrated the company's unique raw material supply with TCI's extensive R&D and manufacturing network.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Desert Lake Technologies.